Cadila Healthcare subsidiary gets 5 observations from USFDA

Published On 2018-09-02 05:15 GMT   |   Update On 2018-09-02 05:15 GMT

Mumbai: Pharma Major Cadila Healthcare said that USFDA inspected the injectables manufacturing facility of Liva Pharmaceuticals Ltd a 100 percent subsidiary of Cadila Healthcare Ltd located at Vadodara.


The inspection was made from August 20 to August 28, 2018, the company said in a filing with BSE.

This was a product-specific Pre Approval Inspection. The inspection concluded with 5 observations. Liva will respond to the USFDA within 15 days.

At present Liva does not export any products to the US market, the filing added.
Article Source : UNI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News